India's Section 3(d) and Compulsory Licensing: How Indian Patent Law Balances Innovation and Affordable Access to Life-Saving Medicines
核心洞察
India's Patents Act, 1970, through provisions like Section 3(d) and compulsory licensing (Sections 84, 92), systematically prioritizes public health access over pharmaceutical patent monopolies.
The landmark 2012 Bayer v. Natco compulsory license granted Natco Pharma the right to produce generic Nexavar, slashing the monthly cost by 97% from ₹2,80,000 to ₹8,800.
Section 3(d) blocks patent "evergreening" by requiring demonstrated therapeutic efficacy for new forms of known substances, upheld in the 2013 Novartis v. Union of India Supreme Court ruling.
India's legal framework for pharmaceutical patents represents one of the most consequential balancing acts in global public health: systematically privileging patient access to affordable medicines while still operating within the international intellectual property system. Through a combination of legislative foresight—most notably Section 3(d) of the Patents Act, 1970, and compulsory licensing provisions under Sections 84 and 92—India has carved out a unique space as the "pharmacy of the developing world," supplying 40% of the United States' generic medicine demands, 50% of Africa's generics, and 60% of global vaccines.
The foundation of this model lies in the Indian Patents Act of 1970, which deliberately placed pharmaceuticals under process patents rather than product patents. This legislative choice enabled domestic companies such as Cipla, Dr Reddy's Laboratories, and Ranbaxy Laboratories to reverse-engineer life-saving drugs through alternative manufacturing methods, producing therapeutically equivalent medicines at a fraction of the cost charged by multinational corporations.
Compulsory Licensing and the Bayer v. Natco Precedent
The most explicit demonstration of India's public health-oriented patent system came in 2012, when the Controller General of Patents, Designs and Trademarks granted the country's first—and to date only—compulsory license to Natco Pharma for Bayer Corporation (搜索)'s cancer drug Sorafenib Tosylate (Nexavar).
Bayer was marketing Nexavar in India at approximately ₹2,80,000 per month, a price point that rendered the drug inaccessible to the vast majority of patients with advanced kidney and liver cancer (搜索). Natco Pharma applied under Section 84 of the Patents Act, arguing that all three statutory conditions for compulsory licensing were met: the reasonable requirements of the public were not satisfied, the drug was not available at a reasonably affordable price, and the patented invention was not worked in India.
The Controller General granted the license, permitting Natco to manufacture and sell its generic version at ₹8,800 per month—a price reduction of approximately 97%—while still compensating Bayer through a 6% royalty on net sales. This case became a global precedent, demonstrating how a developing country's patent system could align with international covenants such as the Doha Declaration on TRIPS and Public Health (2001).
The case also brought to light a controversial statement attributed to Bayer's leadership: "We did not develop this product for the Indian market—let's be honest—we developed this product for Western patients who can afford this product."
Section 3(d): The Shield Against Evergreening
Equally critical to India's pharmaceutical patent architecture is Section 3(d), introduced following India's accession to the TRIPS Agreement in 1995 and the subsequent 2005 amendment that reintroduced product patents. Section 3(d) states that "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" is not patentable.
This provision directly targets "evergreening"—the corporate strategy whereby pharmaceutical companies file successive secondary patents on minor modifications (such as changes in dosage form, polymorphs, or isomers) to extend monopoly protection beyond the original 20-year patent term.
The definitive test of Section 3(d) came in Novartis AG v. Union of India (2013), when the Swiss multinational sought an Indian product patent for the beta-crystalline form of imatinib mesylate, the active ingredient in the leukemia (搜索) drug Gleevec. Although Novartis had globally patented the base molecule in 1993, the Indian Patent Office rejected the 2005 domestic application under Section 3(d).
Novartis appealed, arguing that the beta-crystalline form offered a 30% increase in bioavailability and superior physical stability. The Supreme Court of India, however, ruled that in the context of pharmaceuticals, "efficacy" must be construed strictly as therapeutic efficacy—the actual increased capability of a drug to cure or mitigate an illness. The Court held that minor physical upgrades do not automatically constitute therapeutic advancement, and applicants must provide concrete clinical data proving superior medical outcomes.
The ruling preserved the local generic market for imatinib, slashing monthly treatment costs from approximately ₹1.2 lakhs to ₹8,000.
The API Vulnerability: India's Dependence on China
Despite its dominance in finished generic formulations, India's pharmaceutical industry faces a critical structural vulnerability: approximately 68% of its Active Pharmaceutical Ingredients (APIs)—the biologically active components responsible for a drug's therapeutic effect—are imported from China.
China's dominance in API production was achieved through deliberate state policy, including massive government subsidies, relaxed environmental regulations, and economies of scale that systematically undercut competitors. India, which once maintained a robust domestic API manufacturing base, gradually shifted toward Chinese imports due to their significantly lower cost.
This dependence became starkly visible during the COVID-19 pandemic, when Chinese export restrictions and supply chain disruptions caused severe shortages of raw materials for Indian manufacturers, threatening the supply of essential medicines both domestically and globally.
In response, the Indian government has launched the Production Linked Incentive (PLI) scheme for bulk drugs, providing financial incentives to domestic API manufacturers to revive and expand local production capacity. Additionally, bulk drug parks are being established in states including Himachal Pradesh, Andhra Pradesh, and Gujarat to create dedicated manufacturing ecosystems with shared infrastructure.
A Calibrated Approach to Intellectual Property
According to government and industry officials, India employs a "calibrated approach" to intellectual property protection—one that balances public health, drug accessibility, and domestic industry interests while recognizing the demands of the international intellectual property system. This framework has enabled local companies to prepare manufacturing capacity, supply chains, and raw material sourcing in anticipation of base molecule patent expirations, ensuring rapid generic entry the moment a 20-year patent term concludes.
More recently, the Delhi High Court in F Hoffmann-La Roche AG & Anr v. Natco Pharma Ltd reinforced this patient-centric approach, holding that when a drug is the only one available in India for a rare disease—in this case, Risdiplam for spinal muscular atrophy (搜索)—its availability at an affordable price is a material factor when deciding on interim injunctions in patent disputes.